IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer
16 May 2019 - 9:05PM
Business Wire
Company to host conference call following ASCO
presentation on June 2 to discuss updated clinical data
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology corporation, today announced that the American
Society of Clinical Oncology (ASCO) has published an abstract on
the Company’s clinical study evaluating its lead candidate,
DPX-Survivac, in recurrent advanced ovarian cancer. The abstract
was released online on the ASCO website yesterday in advance of
ASCO’s annual meeting in Chicago, Illinois, taking place May 31 –
June 4, 2019.
The final conference poster presentation will include additional
data collected between the abstract submission cutoff date of
February 12, 2019, and the presentation itself.
Conference Call and Webcast Information
IMV will host a webcast and conference call to provide an
overview of its ASCO presentation on Sunday, June 2, 2019
at 9:00 a.m. ET. The conference line is (866) 211-3204 (U.S.
and Canada) or (647) 689-6600 (International), and the
conference ID# is 8579285. A live audio webcast and presentation
will be available via this link and through the 'Events
and Presentations' page of IMV’s website.
IMV ASCO 2019 Presentation Detail
Poster Title: “DPX-Survivac and intermittent low-dose
cyclophosphamide (CPA) with or without epacadostat (E) in the
treatment of subjects with advanced recurrent epithelial ovarian
cancer (DeCidE1 trial): T cell responses and tumor infiltration
correlate with tumor regression.”Abstract Number:
5576Session Title: Gynecologic CancerDate and Time:
June 1, 2019, 1:15 – 4:15 p.m. CT
About DPX-Survivac
DPX-Survivac is the lead candidate in IMV’s new class of
immunotherapies that programs targeted T cells in vivo. It has
demonstrated the potential for industry-leading targeted,
persistent, and durable T cell activation. IMV believes this
mechanism of action (MOA) is key to generating durable solid tumor
regressions. DPX-Survivac consists of survivin-based peptides
formulated in IMV’s proprietary DPX drug delivery platform.
DPX-Survivac is designed to work by eliciting a cytotoxic T cell
immune response against cancer cells presenting survivin peptides
on their surface.
Survivin, recognized by the National Cancer
Institute (NCI) as a promising tumor-associated antigen, is
broadly over-expressed in most cancer types, and plays an essential
role in antagonizing cell death, supporting tumor-associated
angiogenesis, and promoting resistance to anti-cancer
therapies. IMV has identified over 15 cancer indications in
which the over-expression of survivin can be targeted by
DPX-Survivac.
DPX-Survivac has received Fast Track designation from
the U.S. Food and Drug Administration (FDA) as
maintenance therapy in advanced ovarian cancer, as well
as orphan drug designation status from the
U.S. FDA and the European Medicines
Agency (EMA) in the ovarian cancer indication. It is
currently being evaluated in multiple Phase 1b/2 clinical
trials.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory
approval of DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory
approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190516005231/en/
MEDIAAndrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.comINVESTOR RELATIONSMarc
Jasmin, IMV Senior Director, Investor Relations and
CommunicationsO: (902) 492-1819 ext: 1042M: (514) 917-9481
E: mjasmin@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024